Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07087613 · ClinicalTrials.gov registry record

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

A clinical trial of Heart Failure With Reduced Ejection Fraction and Hypertension, Pulmonary, sponsored by Eko Devices.

Recruiting
Registry status
3,850
Enrollment target
3
Study locations

NCT07087613 is a study of Heart Failure With Reduced Ejection Fraction and Hypertension, Pulmonary that is actively recruiting participants, run by Eko Devices. The registered enrollment target is 3,850 participants, roughly in line with the 3,823-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target. The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07087613, a study of Heart Failure With Reduced Ejection Fraction and Hypertension, Pulmonary, is actively recruiting participants, sponsored by Eko Devices.

RECRUITING
Registry status
3,850 participants
Enrollment target
3
Study locations

Study Summary

This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension (PH) and low left ventricular ejection fraction (EF ≤ 40%). PH is a condition characterized by high blood pressure in the pulmonary arteries, which can lead to heart failure and carries significant risks if undiagnosed. Low EF, which indicates reduced pumping ability of the heart, is also associated with increased risk of severe cardiac events but can remain undetected because patients often have no symptoms or only nonspecific symptoms. In this study, adults undergoing clinically indicated echocardiograms at outpatient sites will be invited to participate. Participants will complete a single study session lasting about 20 minutes, during which heart sounds and a three-lead ECG will be collected using the Eko CORE 500 device. If participants have had a clinical 12-lead ECG within 30 days of their echocardiogram, those data may also be used for analysis. The echocardiogram performed as part of routine care within seven days before or after the Eko CORE 500 recording will serve as the reference standard to confirm the presence or absence of PH and low EF. Up to 3,850 participants may be enrolled across multiple sites to ensure that approximately 3,500 complete the study. The data collected will be used to develop and validate artificial intelligence (AI) algorithms that aim to detect PH and identify low EF, potentially enabling earlier and simpler screening for these conditions in clinical practice.

Interventions

  • DEVICE Eko CORE 500 Digital Stethoscope

Study Locations (3)

Illinois

  • Prairie Cardiovascular - O'Fallon
  • Prairie Education & Research Cooperative - Springfield
  • St Johns Hospital, Springfield - Springfield

Trial Details

FieldValue
Enrollment Target 3,850 participants
Start Date 2025-06-15
Est. Completion 2026-08-31

Sponsor

Eko Devices

16 total trials

What the Registry Record Tells You About NCT07087613

The ClinicalTrials.gov registry entry for NCT07087613 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,850 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 3,823-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target. The listed sponsor is Eko Devices, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which Eko CORE 500 Digital Stethoscope is the first listed.

NCT07087613 reports 3 study locations spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT07087613 about?

NCT07087613 is a clinical study titled "Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG". This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension (PH) and low left ventricular ejection fraction (EF ≤ 40%). PH is a condit...

What is the current status of trial NCT07087613?

This trial is currently recruiting. The enrollment target is 3,850 participants. The study started on 2025-06-15. Estimated completion is 2026-08-31.

What conditions does trial NCT07087613 study?

This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction, Hypertension, Pulmonary.

What interventions are being tested in trial NCT07087613?

The interventions under investigation include: Eko CORE 500 Digital Stethoscope (DEVICE).

Who is sponsoring clinical trial NCT07087613?

This trial is sponsored by Eko Devices, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07087613 being conducted?

This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure With Reduced Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.